Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on Myriad Genetics (NASDAQ:MYGN) and raised the price target from $25 to $28.
July 21, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has maintained a 'Buy' rating on Myriad Genetics and raised the price target from $25 to $28, which could lead to a positive market reaction.
The 'Buy' rating maintained by Goldman Sachs indicates their positive outlook on Myriad Genetics. The increase in price target from $25 to $28 suggests that they expect the stock to perform well in the future. This could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100